<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0185-3252</journal-id>
<journal-title><![CDATA[Anales médicos (México, Ciudad de México)]]></journal-title>
<abbrev-journal-title><![CDATA[An. méd.]]></abbrev-journal-title>
<issn>0185-3252</issn>
<publisher>
<publisher-name><![CDATA[Asociación Médica del Centro Médico ABC]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0185-32522025000400002</article-id>
<article-id pub-id-type="doi">10.24875/amh.25000004</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Radio-pathological agreement of conventional imaging studies to evaluate therapeutic response with neoadjuvant chemotherapy in breast cancer]]></article-title>
<article-title xml:lang="es"><![CDATA[Concordancia radio-patológica de estudios imagenológicos convencionales para evaluar la respuesta terapéutica con quimioterapia neoadyuvante en cáncer de mama]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosales-Rosales]]></surname>
<given-names><![CDATA[Lourdes L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Larios-Cruz]]></surname>
<given-names><![CDATA[Kictzia Y.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Palomares]]></surname>
<given-names><![CDATA[Luis A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad la Salle México Mexican School of Medicine ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Contra el Cánce de Mama A.C Department of Imaging ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Médico Dalinde Department of Imaging ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>70</volume>
<numero>4</numero>
<fpage>260</fpage>
<lpage>268</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0185-32522025000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0185-32522025000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0185-32522025000400002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: The evaluation of pathologic response to neoadjuvant treatment by conventional methods (mastography and ultrasound) has been shown to have greater sensitivity and specificity when assessed together, since mastography has limitations in dense breasts that ultrasound improves, serving as a complementary study.  Objective: The objective of this study was to evaluate the concordance of mastography and ultrasound with the histopathological report to identify tumor response to neoadjuvant systemic therapy in breast cancer.  Material and methods: This was observational, longitudinal, and retrospective cohort study in breast cancer patients treated with neoadjuvant chemotherapy, with mastography, ultrasound, and histopathological report (gold standard). The response to chemotherapy was evaluated using the residual cancer burden criteria. In the statistical analysis, percentages, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and radio-pathological concordance were obtained by means of a weighted Kappa index with 95% confidence interval.  Results: In 52 patients, the use of mastography combined with ultrasound has a sensitivity of 98%, specificity 67%, PPV 96%, NPV 80%, and kappa of 0.70 to identify response to treatment globally.  Conclusion: Mastography and ultrasound together have good concordance with histopathologic report for predicting response to neoadjuvant treatment.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: La evaluación de la respuesta patológica al tratamiento neoadyuvante por métodos convencionales (mastografía y ultrasonido) ha mostrado tener mayor sensibilidad y especificidad al valorarse de manera conjunta, ya que la mastografía tiene limitaciones en mamas densas que el ultrasonido mejora, sirviendo como estudio complementario.  Objetivo: Evaluar la concordancia de la mastografía y ultrasonido con el reporte histopatológico para identificar la respuesta tumoral a la terapia sistémica neoadyuvante en el cáncer de mama.  Material y métodos: Estudio observacional, longitudinal, cohorte retrospectivo, en pacientes con cáncer de mama tratadas con quimioterapia neoadyuvante, con reporte de mastografía, ultrasonido e histopatológico (estándar de oro). Se evaluó la respuesta a quimioterapia utilizando los criterios de RCB. En el análisis estadístico se obtuvieron porcentajes, sensibilidad, especificidad, valor predictivo positivo (VPP), valor predictivo negativo (VPN) y concordancia radio-patológica mediante índice de Kappa ponderada con intervalo de confianza al 95% (IC 95%).  Resultados: En 52 pacientes el uso de la mastografía combinada con ultrasonido tiene sensibilidad del 98%, especificidad 67%, VPP 96%, VPN 80% y kappa de 0.70 para identificar la respuesta al tratamiento de manera global.  Conclusiones: La mastografía y ultrasonido en conjunto tienen buena concordancia con el reporte histopatológico para predecir la respuesta al tratamiento neoadyuvante.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Radio-pathological agreement]]></kwd>
<kwd lng="en"><![CDATA[Neoadjuvant therapy]]></kwd>
<kwd lng="en"><![CDATA[Breast cancer]]></kwd>
<kwd lng="es"><![CDATA[Concordancia radio-patológica]]></kwd>
<kwd lng="es"><![CDATA[Terapia neoadyuvante]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de mama]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gampenrieder]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Peer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weismann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Meissnitzer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rinnerthaler]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Webhofer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiologic complete response (rCR) in contrast-en-hanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemo-therapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)]]></article-title>
<source><![CDATA[Breast Cancer Res]]></source>
<year>2019</year>
<volume>21</volume>
<page-range>19</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makanjuola]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Alkushi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Al Anazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defining radiologic complete response using a correlation of presurgical ultrasound and mammographic localization findings with pathological complete response following neoadjuvant chemotherapy in breast cancer]]></article-title>
<source><![CDATA[Eur J Radiol]]></source>
<year>2020</year>
<volume>130</volume>
<page-range>109146</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortazar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Untch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Costantino]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Wolmark]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<page-range>164-72</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liedtke]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mazouni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hess]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[André]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tordai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mejia]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>1275-81</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Portelles]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Sanz]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Oller]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia neoadyuvante en cáncer de mama, localmente avanzado TT - neoadjuvant chemotherapy in locally advanced breast cancer]]></article-title>
<source><![CDATA[Correo Científico Méd]]></source>
<year>2013</year>
<volume>4</volume>
<page-range>333-442</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mamounas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wieand]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Robidoux]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Margolese]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-18]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1997</year>
<volume>15</volume>
<page-range>2483-93</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rauch]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Adrada]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Kuerer]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Van La Parra]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer]]></article-title>
<source><![CDATA[AJR Am J Roentgenol]]></source>
<year>2017</year>
<volume>208</volume>
<page-range>290-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Litière]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[De Vries]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gwyther]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mandrekar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[RECIST 1.1-Update and clarification: from the RECIST committee]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2016</year>
<volume>62</volume>
<page-range>132-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rea]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tomlins]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Time to stop operating on breast cancer patients with pathological complete response?]]></article-title>
<source><![CDATA[Eur J Surg Oncol]]></source>
<year>2013</year>
<volume>39</volume>
<page-range>924-30</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
